All Pharma News
price-trendAsk Us
Chiesi, Affibody sign $637M respiratory disease collab

Chiesi, Affibody sign $637M respiratory disease collab
FIERCE BIOTECH
08 Mar 2023
Share Share
ACELYRIN, Affibody. Inmagene Biopharma Announce Data from PII Trial of Izokibep

ACELYRIN, Affibody. Inmagene Biopharma Announce Data from PII Trial of Izokibep
PRNEWSWIRE
03 Jun 2022
Share Share
ACELYRIN, Affibody & Inmagene Shows +ve Interim Results from Phase 2 of Izokibep

ACELYRIN, Affibody & Inmagene Shows +ve Interim Results from Phase 2 of Izokibep
PRNEWSWIRE
13 Dec 2021
Share Share
Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials

Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials
Kyle LaHucik FIERCEBIOTECH
16 Nov 2021
Share Share
Affibody and Inmagene announce First Patient Dosed in Phase 2 ASPIRE Trial

Affibody and Inmagene announce First Patient Dosed in Phase 2 ASPIRE Trial
PRESS RELEASE
25 Aug 2021
Share Share
Affibody Announces Initiation of Confirmatory Phase 2 Trial of ABY-035

Affibody Announces Initiation of Confirmatory Phase 2 Trial of ABY-035
MYNEWSDESK
10 Nov 2020
Share Share
Affibody Announces +VE Top-Line Data from Ph 2 Proof-of-Concept Trial of ABY-035

Affibody Announces +VE Top-Line Data from Ph 2 Proof-of-Concept Trial of ABY-035
AFFIBODY
16 Jun 2020
Share Share